Dr Wouter Zandee provides his thoughts on the symptomatic control of functioning pancreatic NET

Video Transcript

My name is Wouter Zandee, I am an Endocrinologist at the University Medical Center Groningen.

And today I will be discussing how to reduce hormone symptoms from functioning pancreatic neuroendocrine tumours (NETs).

These functioning pancreatic NETs are rare but require specific treatment to reduce the symptoms of hypersecretion to increase quality of life.

Symptom Control

Also, symptom control is required to safely perform surgery or to treat with systemic therapy.

In general, two options exist for reduction of symptoms.

First of all reduction of tumour burden can be considered in accordance with the ENETS guidelines. This can be done with surgery, either curative or with debulking surgery or PRRT with Lu177-DOTATATE, and liver directed therapies can be effective.

Specifically, for hormone secretion several options are also available which I would like to discuss in more detail.

First line therapy is generally a somatostatin analogue (SSA) because of low toxicity and proven decreases in hormone secretion.

SSAs can also decrease glucagon secretion, which increases hypoglycemia in small numbers of patients with an insulinoma. So, for patients with an insulinoma the first administration is done clinically.

If an SSA is ineffective in controlling the hormone symptoms, PRRT with Lu177-DOTATATE is especially effective for patients with functioning pNETs. It has a symptomatic response rate of 71% and increases the quality of life for these patients.

Also everolimus can decrease hypoglycemia in patients with an insulinoma.

In case series sunitinib has been prescribed to decrease diarrhoea for patients with a VIPoma. So, these drugs can also be effective for these patients.

Conclusion

In conclusion, adequate control of symptoms is essential for patients with a functioning pNET to increase quality of life.

Generally, SSAs are first line therapy but if these prove ineffective PRRT can be especially effective in these patients.

Thank you for watching on behalf of NET CONNECT.

Dr Wouter Zandee graduated from medical school in 2010 at the Leiden University with a thesis on the surgical treatment of medullary thyroid carcinoma. Thereafter he started his training to become an internist-endocrinologist. He is currently a fellow in endocrinology at the Erasmus Medical Center, Rotterdam, focusing on several types of endocrine tumors. In the neuroendocrine tumor department he is a sub-investigator of multicenter trials. Concurrently he is pursuing a PhD on neuroendocrine tumors, focusing on biomarkers, treatment of hormonal syndromes (mainly with 177Lu-DOTATATE) and quality of care.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Ipsen
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
NET CONNECT

NET CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Ipsen and from Eisai Europe Limited.

Meet the experts

Other programmes of interest

podcast Podcast
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Sep 2024

video Video
Oncology Hemato-oncology 
Early relapsed/refractory multiple myeloma (RRMM): best practices in management

A 3-part video series on managing early RRMM from leading medical experts

Experts
Dr Elena Zamagni, Dr Fredrik Schjesvold, Dr Joseph Mikhael
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Sep 2024

other Other

Episode

2

of 2

episode
Oncology 
Optimising samples for biomarker testing in lung, prostate and gastric cancer

Recommendations for best practice

Experts
Dr Alexander Wyatt, Prof. Frédéric Bibeau
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Aug 2024

Educational programme supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.
publication Publication
Oncology 
Advancing HCC management in Asia: insights from patients and HCPs

Paper published in Journal of Gastrointestinal Cancer

Experts
Prof. Chee-Kiat Tan
  • download Downloadable
    Resources
  • clock 15 MIN
  • calendar Jul 2024

This educational programme is supported by an Independent Educational Grant from Roche.
other Other
Oncology 
Come and visit us in Barcelona at ESMO 2024!

Get your free professional profile photos taken with us at Booth 507

  • clock 1 MIN
  • calendar Jul 2024

micro-learning Micro learning
Oncology Endocrinology Rare diseases 
Tools for optimising treatment & management of advanced NETs

Maximising outcomes for patients with advanced neuroendocrine tumours 

Experts
Prof. Emily Bergsland, Prof. Louis de Mestier
Endorsed by
NANETS
Neuroendocrine Cancer UK
CommNETs
The Healing NET Foundation
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jul 2024

Educational programme supported by an Independent Educational Grant from Ipsen.